AI Article Synopsis
- Anaferon, a pediatric formulation, showed antiviral effects in mice infected with the H1N1 virus, significantly reducing virus production in their lungs.
- Anaferon was administered both therapeutically and prophylactically, leading to a 10-fold decrease in viral load compared to control mice.
- Its effectiveness was comparable to Tamiflu when given before or after the infection.
Article Abstract
Anaferon (pediatric formulation) administered in the therapeutic-and-prophylactic regimen to mice receiving intranasally 100% infecting dose of A/California/07/2009(H1N1)v influenza virus exhibited an antiviral effect and 10-fold reduced the production of influenza virus in the lungs of infected mice on days 4, 6, and 8 after infection compared to the control (distilled water). The efficiency of Anaferon (pediatric formulation) administered before and after infection with A/California/07/2009(H1N1)v influenza virus was not inferior to the use of Tamiflu after infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10517-010-1006-0 | DOI Listing |
Publication Analysis
Top Keywords
influenza virus
16
anaferon pediatric
12
pediatric formulation
12
formulation administered
8
a/california/07/2009h1n1v influenza
8
antiviral activity
4
activity anaferon
4
formulation mice
4
mice infected
4
infected pandemic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!